Therapeutic cancer vaccination with a peptide derived from CALR exon 9 mutations, or the mutant-CALR peptide vaccine combined with keyhole limpet hemocyanin and poly-ICLC, can induce strong cellular immune responses in patients with CALR-mutant MPN. This evidence concerns the gene CALR and myeloproliferative neoplasm.